VAX 102

Drug Profile

VAX 102

Alternative Names: Flagellin.HuM2e; M2e universal influenza vaccine - VaxInnate; M2e-Flagellin; STF2.4xM2e; VAX102

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator VaxInnate
  • Class Antivirals; Influenza A vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus infections

Most Recent Events

  • 22 Sep 2015 No recent reports on development identified - Phase-I for Influenza-A virus infections (Combination therapy, Prevention, In volunteers) in USA (IM)
  • 22 Sep 2015 No recent reports on development identified - Phase-I/II for Influenza-A virus infections (Prevention, In volunteers) in USA (IM & SC)
  • 19 Dec 2011 VaxInnate's recombinant seasonal and pandemic influenza vaccines licensed to CJ CheilJedang Corporation exclusively in South Korea, and non-exclusively in certain South-East Asia countries, excluding China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top